Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

Article Oncology

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

Shukui Qin et al.

Summary: Pembrolizumab significantly prolonged overall survival and progression-free survival in previously treated advanced hepatocellular carcinoma patients from Asia, with a higher objective response rate compared to placebo.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Radiological endpoints as surrogates for survival benefit in hepatocellular carcinoma trials: All that glitters is not gold

Giuseppe Cabibbo et al.

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials

Claudia Angela Maria Fulgenzi et al.

Summary: Direct comparisons across first-line regimens for advanced hepatocellular carcinoma are lacking. This network metanalysis compared first-line systemic treatments for hepatocellular carcinoma and found that ICI + anti-vascular endothelial growth factor combinations, as well as double ICIs, showed the greatest overall survival benefit. However, ICI + kinase inhibitor regimens were associated with greater progression-free survival benefit at the cost of higher toxicity rates.

JHEP REPORTS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function

Giuseppe Cabibbo et al.

Summary: The number of effective systemic therapies for advanced hepatocellular carcinoma is increasing rapidly, with immunotherapy leading to improved survival outcomes. However, many patients still receive tyrosine kinase inhibitors due to contraindications to immune checkpoint inhibitors. Maintaining optimal liver function and managing hepatic decompensation are crucial in defining the treatment sequence.

DIGESTIVE AND LIVER DISEASE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

添加到收藏夹

Editorial Material Oncology

Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead

Ian F. Tannock et al.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley et al.

Summary: This study evaluated the combination of cabozantinib and atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. The combination treatment group showed better progression-free survival compared to the sorafenib group, but overall survival did not reach statistical significance. Common adverse events in the combination group included liver enzyme elevation, hypertension, and skin reactions. The study suggests that cabozantinib plus atezolizumab may be a treatment option, but further research is needed.

LANCET ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

S. Qin et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

S. Qin et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials

Claudia A. M. Fulgenzi et al.

Summary: This study compared the efficacy of first-line treatment options for patients with unresectable hepatocellular carcinoma and found that atezolizumab plus bevacizumab had a lower risk of death compared to other drugs. However, there was no statistically significant advantage compared to other combination therapies. Nevertheless, this treatment regimen was associated with a higher risk of grade 3 adverse events.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma

Giuseppe Cabibbo et al.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma

Giuseppe Cabibbo et al.

Summary: The surrogate relationship between PFS and OS varies depending on treatment class and evaluation time-point in immunotherapy trials for HCC. In ICI trials, Q1-PFS and 12-month PFS-RMST are robust surrogate endpoints for OS.

CANCERS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Combined hepatocellular-cholangiocarcinoma: An update

Maria Reig et al.

Summary: The potential impact of DAAs in BCLC-B/C stage patients with HCC is understudied, as HCC patients have been excluded from DAA trials. The decision on using DAAs should be made based on individual patient profiles.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Oncology

First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials

Giuseppe Cabibbo et al.

Summary: A simulation model comparing different first-line immunotherapy and second-line systemic treatment sequences in advanced HCC patients found that ATEZO plus BEVA followed by LENVA or SORA was the most effective sequence. The study suggests that future evidence from clinical trials and real-world studies is needed to validate the benefits of sequential treatment options.

LIVER CANCER (2021)

添加到收藏夹

Article Oncology

Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

Arndt Vogel et al.

Summary: This study conducted indirect comparisons of treatments for first-line locally advanced or metastatic unresectable HCC patients who had not received prior systemic treatment. Results showed that atezolizumab-bevacizumab had improved overall survival compared to other treatment options, indicating its potential superiority for these patients.

LIVER CANCER (2021)

添加到收藏夹

Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology